<DOC>
	<DOCNO>NCT02695459</DOCNO>
	<brief_summary>Phase II , open-label , multicentre national study . Patients metastatic neuroendocrine carcinoma extrapulmonary origin eligible . Treatment perform indicated section `` Investigational drug reference therapy '' . Cisplatinum everolimus dose base upon early phase 1 study ( Fury et al . 2012 ) . CTs do 9 weekly interval ( 3 course chemotherapy ; ) . Patients treat documented progression accord RECIST 1.1 . Enrolment expect take 14 - 16 month . The total study duration estimate 2 3 year publication . Three NET centre The Netherlands participate , ( Erasmus Medical Center Rotterdam , Netherlands Cancer Institute Amsterdam , University Medical Center Groningen ) A pre-treatment ( optional post-treatment ) tumour biopsy include DNA/RNA analysis organoid culture . An additional 5cc blood withdrawn germline DNA reference . A second 5 cc blood include measure circulate tumour transcript identify type GEP-NET ( NETTest ) .</brief_summary>
	<brief_title>Cisplatinum Everolimus Patients With Metastatic Unresectable NEC Extrapulmonary Origin</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Pathologically confirm unresectable locally advanced and/or metastatic NEC extrapulmonary origin ( WHO 2010 classification ; Ki67 &gt; 20 % ) curative ( chemoradiation ) treatment option available ( include merkel cell carcinoma ) . 2 . Measurable disease accord RECIST 1.1 , CTscan MRI 3 . ECOG Performance status 02 ( see Appendix 2 ) 4 . Adequate bone marrow function show : ANC≥1.5 x 109/L , Platelets ≥100 x 109/L , Hb &gt; 6 mmol/L 5 . Adequate liver function show : Total serum bilirubin ≤1.5 ULN ALT AST ≤2.5x ULN ( ≤5x ULN patient liver metastasis ) 6 . Adequate renal function : calculate creatinin clearance &gt; 60ml/min . ( CockcroftGault formula ) 7 . Life expectancy least 3 month . 8 . Male female age ≥ 18 year . 9 . Signed informed consent . 10 . Able swallow retain oral medication . 11 . Locally advanced metastatic lesion ( ) histological biopsy safely obtain : Patients safely accessible locally advanced metastatic lesion ( ) include bone lesion . Patients know bleed disorder ( hemophilia ) bleeding complication biopsy , dental procedure surgery . Patients use anticoagulant medication time biopsy : aspirin derivative , NSAID 's , coumarines , platelet function inhibitor , heparin ( include LMWHs ) oral factor Xa inhibitor allow , unless medication either safely stop counteract . Adequate coagulation status measure : PT &lt; 1.5 x ULN PTINR &lt; 1.5 APTT &lt; 1.5 x ULN On day biopsy patient use coumarines : PTINR &lt; 1.5 12 . Patients known contraindication lidocaine ( derivative ) 1 . Previous chemotherapy metastatic unresectable NEC extrapulmonary origin . ( prior perioperative chemotherapy chemoradiation curative intention allow least 6 month elapse completion therapy enrolment study ) . 2 . Prior therapy mTOR inhibitor ( e.g . sirolimus , temsirolimus , deforolimus , everolimus ) 3 . Other malignancy within last 5 year , except carcinoma situ cervix , basal cell carcinoma . 4 . Known intolerance hypersensitivity everolimus rapamycin analog ( e.g . sirolimus , temsirolimus ) cisplatinum 5 . Known impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral everolimus 6 . Uncontrolled diabetes mellitus define HbA1c &gt; 8 % despite adequate therapy . Patients known history impair fast glucose diabetes mellitus ( DM ) may include , however blood glucose antidiabetic treatment must monitor closely throughout trial adjust necessary 7 . Patients severe and/or uncontrolled medical condition : a. unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤6 month prior randomization , serious uncontrolled cardiac arrhythmia poorly control hypertension ( systolic BP &gt; 180 mmHg diastolic BP &gt; 100 mmHg ) ; . b. active uncontrolled severe infection , c. liver disease cirrhosis , decompensated liver disease , know history chronic hepatitis d. know severely impaired lung function ( spirometry DLCO 50 % less normal O2 saturation 88 % less rest room air ) , e. active , bleeding diathesis ; 8 . Chronic treatment corticosteroid immunosuppressive agent 9 . Known history HIV seropositivity 10 . Pregnant nursing ( lactate ) woman 11 . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 6 month stop study treatment . 12 . Sexually active male , unless use condom intercourse take study medication 6 month stop study medication . 13 . Patients dyspnoea rest due complication advance malignancy disease , require supportive oxygen therapy . 14 . History clinical evidence brain metastasis . 15 . Any investigational drug treatment within 4 week start study treatment . 16 . Radiotherapy within 4 week start study treatment ( 2 week interval allow palliative radiotherapy give bone metastatic site peripherally patient recover acute toxicity ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>